Nageatte Ibrahim, Author at Arc Nouvel

23 Jan

Articles
No Comments

Cancer Vaccines in the Checkpoint Era: Neoantigens, mRNA, and Phase 3 Progress

Cancer vaccines have been pursued for decades, yet repeated late-stage disappointments led many to doubt whether therapeutic vaccination could ever deliver meaningful clinical benefit. Those disappointments were not only about antigen choice, they were also about immune context: many early...

16 Jan

Articles
No Comments

Why Cancer Drugs Fail FDA Approval: How Clinical Trial Teams Can Prevent Rejection Early

In oncology drug development, FDA rejection is often perceived as a late-stage failure, an FDA Complete Response Letter (CRL) that arrives after many years of pre-clinical development, years of intense clinical work, heavy capital investment, and deep, persistent patient needs....

14 Jan

Articles
No Comments

6 Oncology Drugs Likely to Receive FDA Approval in 2026: A Clinical and Regulatory Analysis

Each year, the oncology development landscape becomes noisier. Late-stage assets are promoted aggressively, conference headlines amplify early signals, and investor narratives often blur the line between promise and probability. After more than 12 years leading global clinical programs across major...

23 Sep

Announcement
No Comments

Arc Nouvel Showcases Innovation at BioTechX USA in Philadelphia

Arc Nouvel Debuts in Philadelphia at BioTechX USA with an Exhibitor Booth featured in the Start-Up Zone of the conference as well as presenting a poster. It was wonderful to connect with so many companies and colleagues in the business. We are looking...

08 Sep

Articles
No Comments

She’s Gone and Done It: The Inspiring Journey of Dr. Nageatte Ibrahim

At the crossroads of medicine, science, and innovation stands Dr. Nageatte Ibrahim—a physician, scientist, and global leader whose work has reshaped the fight against cancer. Best known for her role in the development of Keytruda, one of the most groundbreaking...

Nageatte Ibrahim

Cancer Vaccines in the Checkpoint Era: Neoantigens, mRNA, and Phase 3 Progress

Why Cancer Drugs Fail FDA Approval: How Clinical Trial Teams Can Prevent Rejection Early

6 Oncology Drugs Likely to Receive FDA Approval in 2026: A Clinical and Regulatory Analysis

Arc Nouvel Showcases Innovation at BioTechX USA in Philadelphia

She’s Gone and Done It: The Inspiring Journey of Dr. Nageatte Ibrahim

Contact us Now

Menu

Contact Us

Follow Us